Skip to main content
Premium Trial:

Request an Annual Quote

New German Biotech Company Will Include Bioinformatics Staff


COLOGNE--A new biotechnology company is opening here that will use bioinformatics to help identify and validate drug screening targets in model vertebrate systems for drug development. Artemis Pharmaceuticals is being cofounded by Exelixis Pharmaceuticals, South San Francisco, Calif., which will also provide bioinformatics and other assistance to the start-up.

Artemis will have offices in here and in Tuebingen, and will work with Exelixis on a platform of model genetic screening systems. Exelixis, a genomics company focused on model system genetics for drug-target discovery and validation, will share its genetic map and mutant repository database with Artemis, and also provide Internet connectivity, according to Geoffrey Duyk, Exelisis's chief scientific officer. Exelixis will provide Artemis with its fruit fly and nematodes experience and will make a significant minority investment in the German firm. In return, Artemis and its cofounders will provide Exelixis with expertise in zebrafish and mouse genetics. As Artemis builds a 40-person staff over the next 18 months, it will likely hire three to five people to work in informatics, Duyk told BioInform.

Exelixis has a 10-person bioinformatics staff. He noted that the two firms could merge down the road. Artemis's scientific founders are Nobel laureate Christiane Nusslein-Volhard of the Max Planck Institute, Klaus Rajewsky of the University of Koeln, and Peter Stadler, former head of biotechnology at Bayer AG.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.